DY6 shares rose 10.9% to AUD 0.255 on 10 July after extending reconnaissance activities at its Central Rutile Project.

Macquarie Research sees a 64.94% upside, issuing an OUTPERFORM rating with a price target of AUD 27.00.

Highlights

Island Pharmaceuticals Limited (ASX:ILA)has entered into a binding asset purchase agreement to acquire the Galidesivir antiviral program from BioCryst Pharmaceuticals Inc. The acquisition follows a previously announced Letter of Intent in September 2024 and will add a second clinical-stage antiviral asset to Island’s portfolio.